SCHEMBL1891065

SCHEMBL1891065

NC(=O)c1ccc(Cl)cc1Cl.O=S(=O)(O)c1ccc(N2CCN(c3ccccn3)CC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.53
KDM4E B2RXH2 7/20 0.52
PKM P14618 2/20 0.52
ALDH1A1 P00352 6/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KMT2A Q03164 3/20 0.48
EPHX2 P34913 1/20 0.48
DRD4 P21917 2/20 0.47
LMNA P02545 3/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 2/20 0.46
MAPK1 P28482 2/20 0.46
ADRB2 P07550 1/20 0.46
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ITGB2 P05107 1/20 0.46
ICAM1 P05362 1/20 0.46
ITGAL P20701 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1881316 0.90 KDM4E (0.52) HSD17B10KDM4EPKMALDH1A1SMN1; SMN2
SCHEMBL1885482 0.90 KMT2A (0.47) KDM4EPKMALDH1A1KMT2ALMNA
SCHEMBL4370293 0.89 KMT2A (0.47) HSD17B10KDM4EPKMALDH1A1SMN1; SMN2
SCHEMBL4371258 0.88 KMT2A (0.49) HSD17B10KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL4368494 0.86 ALDH1A1 (0.44) HSD17B10ALDH1A1KMT2A
SCHEMBL4370241 0.86 ALDH1A1 (0.58) HSD17B10KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL1882731 0.84 ALDH1A1 (0.43) ALDH1A1KMT2ADRD4LMNAMAPT
SCHEMBL4379844 0.84 KMT2A (0.46) ALDH1A1SMN1; SMN2KMT2ALMNAMAPT
SCHEMBL1891063 0.83 FLT1 (0.56) HSD17B10KDM4EPKMALDH1A1SMN1; SMN2
SCHEMBL4379291 0.82 KMT2A (0.44) ALDH1A1SMN1; SMN2KMT2ALMNATNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US claimed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US claimed
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US disclosed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS STS, TPMT, DPYD HSD17B10 3340/4885KDM4E 3112/4885PKM 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.